Prenatal urinary metabolites of polycyclic aromatic hydrocarbons and toddler cognition, language, and behavior

Erin R Wallace1, Yu Ni1, Christine T Loftus1

  • 1Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, WA, USA.

Environment International
|December 13, 2021
PubMed

Insights

Prenatal exposure to polycyclic aromatic hydrocarbons (PAHs) showed some links to toddler neurodevelopmental issues in a U.S. study. Certain PAH metabolites were associated with neurodevelopmental delay and altered cognitive and language scores.

Area of Science:

  • Environmental Health
  • Neurodevelopmental Toxicology
  • Epidemiology

Background:

  • Animal and epidemiological studies suggest prenatal exposure to polycyclic aromatic hydrocarbons (PAHs) may negatively impact toddler neurodevelopment.
  • PAHs are environmental pollutants linked to various adverse health outcomes.

Purpose of the Study:

  • To investigate the association between prenatal exposure to PAHs and neurodevelopmental outcomes in toddlers.
  • To examine specific PAH metabolites and their impact on cognitive, language, and behavioral development.

Main Methods:

  • Study included 835 mother-child pairs from a diverse pregnancy cohort in the U.S.
  • PAH metabolite concentrations measured in maternal urine during mid-pregnancy.
  • Neurodevelopmental outcomes assessed using Bayley Scales of Infant and Toddler Development (Bayley-3) and Brief Infant and Toddler Social Emotional Assessment (BITSEA).
  • Multivariate regression and Weighted Quantile Sum Regression (WQS) used to analyze associations.

Main Results:

  • 1-hydroxypyrene associated with increased risk of neurodevelopmental delay at age 2.
  • 1-hydroxynaphthalene associated with lower risk of behavior problems at age 2.
  • Combined 1- and 9-hydroxyphenanthrene associated with higher cognitive scores at age 3.
  • PAH mixtures showed associations with both lower language and higher cognitive scores at different ages.

Conclusions:

  • The study provides some support for adverse associations between prenatal PAH exposure and neurodevelopment in a southern U.S. population.
  • Specific PAH metabolites may have differential effects on various aspects of neurodevelopment.
  • Further research is needed to understand the complex mixture effects of PAHs on child development.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
27
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.0K
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
422